Etanercept: Efficacy and safety

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 4, 2009, Pages 402-405

  Jimenez Puya R ^a   Gomez Garcia F ^a   Amorrich Campos, V ^a   Moreno Gimenez J C ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Efficacy; Etanercept; Psoriasis; Safety

Indexed keywords

ETANERCEPT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IRON DEFICIENCY ANEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; SIDE EFFECT; TUBERCULOSIS;

HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 62149095689     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.03063.x     Document Type: Article

References (10)

1. Smith CH, Anstey AV, Barker JN et al. Directives of the British Association of Dermatologist relatives to the use of biological therapies in the psoriasis. Br J Dermatol 2005 153 : 486 497.
2. Gottlieb AB, Matheson RT, Lowe N, Krueger GG et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 139 : 1627 1623.
3. Papp K, Tyring S, Lahfa M, Prinz J, Griffiths CE et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 152 : 1304 1312.
4. Gordon K, Gottlieb A, Leonardi C et al. Clinical response in psoriasis patients discontinued from an then reinitiated on etanercept therapy. J Dermatol Treat 2006 17 : 9 17.
5. Leonardi CL, Elewski B, Camisa C, Zitnik R. The efficacy and safety of Etanercept in the retreatment of psoriasis after relapse. Poster 568 - 62nd Annual meeting of the American Academy of Dermatology; February 6-11; Washington, DC, 2004.
6. Van de Kerkhof P. Etanercept efficacy and safety in the retreatment of psoriasis after relapse. J Eur Acad Dermatol Venereol 2004 18 : 249.
7. Langley R. High response due to persistent treatment of psoriasis with etanercept. 10th International Psoriasis Symposium. Toronto (Canada), 2004.
8. O'Connor PG, Shi JM, Henry S, Durante AJ, Friedman L, Selwyn PA. Tuberculosis chemoprophylaxis using a liquid isoniazid-methadone admixture for drug users in methadone maintenance. Addiction 1999 94 : 1071 1075.
9. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 2022.
10. Weinblatt M, MD, Brigham & Women's Hospital, Boston, MA, United States; Genovese M, MD, Stanford University Medical Center, Palo Alto, CA, United States; Moreland L, MD. University of Alabama, Birmingham, AL, United States Bathon J, MD, Johns. Hopkins University, Baltimore, MD, United States. Safety and efficacy of up to nine years of etanercept therapy in North American patients with rheumatoid arthritis. 65th Annual Meeting of AAD, February 7, Washington DC.